Drugs / SeroVital
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT02987868 Comparator | Oct → Dec 2011 | — | Pennington Biomedical Research Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SeroVital | “the investigators recently reported that oral administration of a 2.9g/dose of SeroVital, a blend of l-lysine HCl, l-arginine HCL, oxo-proline, N-acetyl-l-cysteine,...” NCT02987868 ↗ |
| Action | Inhibit | “The conservation of T3 levels suggests that the mechanism for increased hGH secretion by the test supplement is through somatostatin inhibition.” PMID 33030391 ↗ Oct 2020 |
| Modality | Other / unclassified | “an amino acid-based dietary supplement” NCT02987868 ↗ |
| Route | Oral | “oral administration of a 2.9g/dose of SeroVital” NCT02987868 ↗ |